Publications & Presentations
Identification of kidney disease diagnoses in patients with diabetes by biopsies and electronic health records
Eva Fast, Cami R. Jones, Kenn B. Daratha, Susanne B. Nicholas, Radica Z. Alicic, Cynthia C. Nast, Jonathan E. Zuckerman, Sarthak Patel, Ken Allison, Adam Tebbe, Michelle Penny, Keith C. Norris, Katherine R. Tuttle.
A highly efficient and reproducible differentiation protocol for iPSC-derived podocytes
Sergii Kyrychenko, Justin Gallagher, Timothy Norman, Alyssa Fanelli, Xiang Pan, Eva Fast, Anna Rachel Gallagher, Thomas Gustafson, Maria D Lalioti.
The Kidney Genome Atlas – a resource to understand APOL1 and other genetic drivers of adult proteinuric kidney diseases
Eva Fast, Thomas Soare, Hari Somineni, James Watkins, Adam Tebbe, Maria Lalioti, Liron Walsh, Matthias Kretzler, Girish N. Nadkarn, Rasheed A. Gbadegesin, Jamie L. Wenke, Daniel G. Macarthur, Peter H. Mundel1, Thomas T. Tibbitts, Michelle Penny
Phase 1, Randomized, Controlled Trial of GFB-024 in Healthy Overweight and Obese Participants and in Participants with Type 2 Diabetes Mellitus
Gregory A. Gaich, John Lawler, Yossi Dagon, Thomas A. Gustafson, Leslie Johnson, Lori Rudolph-Owen
GFB-887
Our lead product candidate, GFB-887 is designed specifically to treat people with kidney diseases associated with an over-activation of the TRPC5-1 pathway.
GFB-024
Our second product candidate is intended to treat patients with severe insulin resistant diabetic nephropathy (SIRDN) and CB1 pathway overactivation.